FDA-cleared profile

AI4CMR v2.0

Ai4medimaging Medical Solutions S.A. · MRI · FDA-cleared (510(k))

Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Clinical role
Segmentation and measurement support
Images and patients
MRI · Heart/Cardiovascular
Key limitation
Keep in mind: 2D flow model is not for patients under 18, 4D flow, extreme congenital distortion or low-SNR data; clinician review/editing is required.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Heart/Cardiovascular Input: DICOM 1.5T or 3T cardiac MR cine and two-dimensional phase-contrast flow acquisitions
  • Who uses it?Intended users: Trained medical professionals interpreting cardiac MR
  • What does the software produce?Output: LV/RV volumes, ejection fraction, mass and indexed measurements; aortic/pulmonary vessel masks and forward/backward/net flow, regurgitant fraction, maximum velocity and pressure gradient.
  • What is its most important limitation?Key limitation: 2D flow model is not for patients under 18, 4D flow, extreme congenital distortion or low-SNR data; clinician review/editing is required.

Clinical takeaway. Clinical role: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Evidence takeaway. Evidence from the reviewed source record: FDA flow-model validation used 167 cases from 61 subjects. The packet contains multiple Dice contexts, so no single Dice result is presented.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Cardiac MRI ventricular function and 2D phase-contrast flow quantification
  • Exact FDA submission
  • Checked 2026-09-05
Workflow role
Segmentation and measurement support
  • Exact FDA submission
  • Checked 2026-09-05
Required input
DICOM 1.5T or 3T cardiac MR cine and two-dimensional phase-contrast flow acquisitions
  • Exact FDA submission
  • Checked 2026-09-05
Output and clinician action
LV/RV volumes, ejection fraction, mass and indexed measurements; aortic/pulmonary vessel masks and forward/backward/net flow, regurgitant fraction, maximum velocity and pressure gradient.
  • Exact FDA submission
  • Checked 2026-09-05
Care setting
Adult
  • Exact FDA submission
  • Checked 2026-09-01

Patient-population text reported in the exact-submission ACR model card; institutional setting may still require vendor confirmation.

Intended users
Trained medical professionals interpreting cardiac MR
  • Exact FDA submission
  • Checked 2026-09-05
Limitations
2D flow model is not for patients under 18, 4D flow, extreme congenital distortion or low-SNR data; clinician review/editing is required.
  • Exact FDA submission
  • Checked 2026-09-05
Evidence summary
FDA flow-model validation used 167 cases from 61 subjects. The packet contains multiple Dice contexts, so no single Dice result is presented.
  • Exact FDA submission
  • Checked 2026-09-05

Exact FDA flow-model validation is stated without pooling it with the separate ACR regulatory summary or promoting a single Dice result.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
FDA flow-model validation used 167 cases from 61 subjects. The packet contains multiple Dice contexts, so no single Dice result is presented.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05

Exact FDA flow-model validation is stated without pooling it with the separate ACR regulatory summary or promoting a single Dice result.

Reported sensitivity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

Segmentation agreement does not establish diagnostic sensitivity.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-05

No diagnostic specificity established.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

AI4CMR v2.0 ACR regulatory performance study summary

  • DesignStandalone performance summary
  • PopulationAdult
  • Scopeexact submission
  • Tested version2
  • Samplen=296
  • Sites1
  • IndependenceIndependence not established

K252084

Preserved baseline ACR study. Exact FDA flow validation is described separately and should not be assumed the same cohort.

K252084 flow-model validation

  • DesignModel validation dataset
  • PopulationCardiac MR flow cases from 61 subjects
  • Scopeexact submission
  • Tested versionAI4CMR v2.0 flow model
  • Samplen=167
  • IndependenceIndependence not established

K252084

Detailed FDA sections contain inconsistent Dice contexts; no numeric score is promoted.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Pricing is recorded, but no exact-product procurement price with a stated offer scope is published in the reviewed sources.

Public pricing
Vendor advertises a pay-per-exam commercial model; rate and v2.0 contract terms not public in reviewed material.
  • Product family
  • Checked 2026-09-05

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM 1.5T or 3T cardiac MR cine and two-dimensional phase-contrast flow acquisitions

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-05 · AI4CMR v2.0: K252084 decision and 510(k) summary

  2. Routing

    Source context, not route validation: Cloud plug-in service implemented through a third-party DICOM viewer interface to PACS/scanner workflow

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-05 · AI4CMR v2.0: K252084 decision and 510(k) summary

  3. AI processing

    Unresolved route: Not established for the exact route.

    Scope: Exact FDA submission. Cloud plug-in architecture does not establish data region, retention or local implementation configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-05 ·

  4. Returned objects

    Source context, not route validation: LV/RV volumes, ejection fraction, mass and indexed measurements; aortic/pulmonary vessel masks and forward/backward/net flow, regurgitant fraction, maximum velocity and pressure gradient.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-05 · AI4CMR v2.0: K252084 decision and 510(k) summary

  5. Viewer/worklist/report

    Unresolved route: LV/RV volumes, ejection fraction, mass and indexed measurements; aortic/pulmonary vessel masks and forward/backward/net flow, regurgitant fraction, maximum velocity and pressure gradient.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-05 · AI4CMR v2.0: K252084 decision and 510(k) summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Integration
Cloud plug-in service implemented through a third-party DICOM viewer interface to PACS/scanner workflow
  • Exact FDA submission
  • Checked 2026-09-05
Security
AI4CMR's security & compliance page states that AI4CMR operates cloud sites in multiple global regions so that data remains within the appropriate jurisdiction in compliance with GDPR and local data-protection regulations, and maintains cloud-based disaster recovery systems to preserve availability and data integrity.
  • Product family
  • Checked 2026-10-27

Vendor statement, not an attestation. The page names the AI4CMR product without distinguishing v1.0 (K220624) from v2.0 (K252084); exact-release scope is not established. The page's listed QMS/regulatory standards (ISO 13485, ISO 14971, IEC 62304, MDR, 21 CFR 820) are not treated as security evidence; no certificate or report was read.

Current interoperability

Vendor describes DICOM, HL7 and FHIR integration options.

product family · checked 2026-09-05

Current page does not establish exact v2.0 implementation compatibility.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K252084
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-05
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2026-02-11
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-06Last searched
21Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

Stored PubMed and clinical-trial arrays are empty and were screened. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, acr ai central product, fda decision summary, vendor product page, literature index, trial registry, recall database, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-10-26 - Exact FDA submission

    Bounded web search on 2026-10-26 (query: "Ai4medimaging reimbursement CPT"; top results reviewed) found no vendor or payer page stating coding, coverage or payment for this product. No result was a vendor or payer page naming this product with coding or payment; any results were general billing guidance. This records what was found, not that none exists.

  • Deployment: Not verified - checked 2026-09-05 - Exact FDA submission

    Cloud plug-in architecture does not establish data region, retention or local implementation configuration.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-05 - Exact FDA submission

    CMR reader training and flow-editing requirements require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-05 - Exact FDA submission

    Version-update validation and flow-edit monitoring require confirmation.

9 sources - 3 history items

Source ledger

  1. K252084 FDA decision source

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, purpose, modality, anatomy

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. AI4CMR v2.0 model card (K252084)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: purpose, modality, intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. AI4CMR v2.0: K252084 decision and 510(k) summary

    U.S. Food and Drug Administration - Accessed 2026-09-05

    Scope: identity, clinical, evidence, implementation

  8. AI4CMR integration and interoperability

    Ai4medimaging - Accessed 2026-09-05

    Scope: implementation, economics

  9. AI4CMR: Security & Compliance

    AI4MedImaging Medical Solutions S.A. - Accessed 2026-10-27

    Scope: security

Research history

  1. K252084 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K241922

Myomics

Phantomics Inc.

Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2025-02-28
FDA-cleared K223523

Sonic DL

GE Medical Systems,LLC (GE Healthcare)

Sonic DL is deep-learning MRI reconstruction for highly undersampled or accelerated cardiac acquisitions on compatible GE 1.5T and 3.0T MRI systems for pediatric and adult patients.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2023-05-30
FDA-cleared K183274

RTHawk, HeartVista Cardiac Package

HeartVista, Inc.

Accessory acquisition, reconstruction, and display of cardiovascular MR images on compatible 1.5T and 3T whole-body MRI systems for trained-physician interpretation.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2019-10-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history